Abstract:The authors regretted to find the mis-representative images in Fig. 3a, c and Fig. 4a, c when re-read our previously published article Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro (DOI: 10.1038/aps.2015.42) in the journal of Acta Pharmacologica Sinica. This mistake occurred due to the careless compilation when the authors tried to show the synergistic effect against tumor apoptosis during figure presentation process. The right Fig. 3a, c and Fig. 4a, c were provided below. Despite that this correction does not affect the results and conclusions of the aforementioned paper, all the authors still consent on the correction of this negligence. We apologize to the Editor and the readership of the journal for any inconvenience caused. Your thoughtful understanding is highly appreciated.

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Author Correction: Targeted Inhibition of STAT/TET1 Axis As a Therapeutic Strategy for Acute Myeloid Leukemia

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Erratum To: Biological Evaluation of Antibody-Maytansinoid Conjugates As a Strategy of RON Targeted Drug Delivery for Treatment of Non-Small Cell Lung Cancer

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Erratum: Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs

Erratum: Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

Correction To: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells: the Effect of Combining RNA Interference with Tyrosine Kinase Inhibitors or Cetuximab

Correction to: Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway (Journal of Experimental and Clinical Cancer Research (2018) 37 (53) DOI: 10.1186/s13046-018-0703-9)

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

Erratum to: Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates (Nature Biomedical Engineering, (2018), 2, 5, (279-292), 10.1038/s41551-018-0221-2)

Correction To: Novel Smac Mimetic APG-1387 Elicits Ovarian Cancer Cell Killing Through TNF-alpha, Ripoptosome and Autophagy Mediated Cell Death Pathway

Author Correction: Synergistic Suppression of Human Breast Cancer Cells by Combination of Plumbagin and Zoledronic Acid in Vitro

Author correction to ‘Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers’ [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

Correction To: Proteogenomic Characterization and Comprehensive Integrative Genomic Analysis of Human Colorectal Cancer Liver Metastasis

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Erratum to: A novel GSH responsive poly(alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy

Correction: Corrigendum: Patient-specific Hepatocyte-Like Cells Derived from Induced Pluripotent Stem Cells Model Pazopanib-Mediated Hepatotoxicity

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study.